Resource

In December, a U.S. judge upheld the New York Attorney General's request for an injunction requiring the powerful Big Pharma company Actavis to continue marketing a lower-cost version of its Alzheimer's drug Namenda, instead of using a "product-hopping" scheme to move consumers to a newer but virtually identical version that would enjoy monopoly protection until 2029, making it unlikely that lower-cost generic alternatives could successfully enter the market. We joined other leading groups, including Consumers Union and Public Citizen, in a friend-of-the-court brief to the U.S. Second Circuit Court of Appeals supporting General Eric Schneiderman's defense against Actavis in its appeal. Our brief is attached.